News archive
-
2023
New publication with the contribution of LYO-X on a population pharmacokinetic model that describes cefepime (FEP) and enmetazobactam (ENM) plasma PK in adult cUTI/ AP patients27. November, 2023New poster on the prediction of an antibody's half-life in human from preclinical data at the Basel Festival of Biologics (10-12 October 2023)11. October, 2023
...
New posters with the contribution of LYO-X presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 202321. September, 2023Joint LYO-X/ ETH D-BSSE Block Course on Modeling and Simulation in Drug Development11. September, 2023
...
New publication with the contribution of LYO-X on the better aligned Alzheimer's Q-ATN model17. July, 2023
...
-
2022
LYO-X and iBX are co-locating in the city centre of Basel!15. September, 2022We are excited to announce that from the 1st July 2022, LYO-X AG is co-locating with Integrated Biologix GmbH in the beautiful city centre of Basel.
...LYO-X has moved to the center of the beautiful town of Basel09. May, 2022We are excited to announce that on the 1st April 2022, LYO-X has moved to the center of the beautiful town of Basel!
...LYO-X will be recruiting at the Forum EPFL 202203. October, 2022Curious to learn more about LYO-X AG? Then join us at the Forum EPFL at the Swisstech Convention Center in Lausanne:
2021
LYO-X will be recruiting at the Forum EPFL07. October, 2021Come and see us in booth C15 at the SwissTech Convention Center in Lausanne.
...Keep an eye on your target - Why increasing the half-life of your antibody is not always the solution.22. June, 2021
...
2020
